Ten-year patterns of stent thrombosis after percutaneous coronary intervention with new- versus early-generation drug-eluting stents: insights from the DECADE cooperation.

[1]  G. Stone,et al.  Long-term follow-up after ultrathin vs. conventional 2nd-generation drug-eluting stents: a systematic review and meta-analysis of randomized controlled trials. , 2021, European heart journal.

[2]  P. Serruys,et al.  10-Year Follow-Up of Patients With Everolimus-Eluting Versus Bare-Metal Stents After ST-Segment Elevation Myocardial Infarction. , 2021, Journal of the American College of Cardiology.

[3]  S. Windecker,et al.  Patient-tailored antithrombotic therapy following percutaneous coronary intervention , 2021, European heart journal.

[4]  S. Saito,et al.  Outcomes After First- Versus Second-Generation Drug-Eluting Stent Thrombosis (from the REAL-ST Registry). , 2020, The American journal of cardiology.

[5]  H. Schunkert,et al.  10-Year Outcomes From a Randomized Trial of Polymer-Free Versus Durable Polymer Drug-Eluting Coronary Stents. , 2020, Journal of the American College of Cardiology.

[6]  H. Bøtker,et al.  10-year outcomes from a randomized comparison of zotarolimus-eluting and sirolimus-eluting stents: the SORT OUT III study. , 2019, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[7]  P. Serruys,et al.  Drug-eluting or bare-metal stents for percutaneous coronary intervention: a systematic review and individual patient data meta-analysis of randomised clinical trials , 2019, The Lancet.

[8]  S. Saito,et al.  Risk Factors and Long-Term Clinical Outcomes of Second-Generation Drug-Eluting Stent Thrombosis. , 2019, Circulation. Cardiovascular interventions.

[9]  H. Schunkert,et al.  Ten-Year Clinical Outcomes From a Trial of Three Limus-Eluting Stents With Different Polymer Coatings in Patients With Coronary Artery Disease: Results From the ISAR-TEST 4 Randomized Trial , 2019, Circulation.

[10]  G. Stone,et al.  Newer-Generation Ultrathin Strut Drug-Eluting Stents Versus Older Second-Generation Thicker Strut Drug-Eluting Stents for Coronary Artery Disease: Meta-Analysis of Randomized Trials , 2018, Circulation.

[11]  A. Nasis,et al.  Polymer‐free versus permanent polymer‐coated drug eluting stents for the treatment of coronary artery disease: A meta‐analysis of randomized trials , 2018, Journal of interventional cardiology.

[12]  Volkmar Falk,et al.  2018 ESC/EACTS Guidelines on myocardial revascularization. , 2018, European heart journal.

[13]  S. Bangalore,et al.  Meta-Analysis of Randomized Clinical Trials Comparing Biodegradable Polymer Drug-Eluting Stent to Second-Generation Durable Polymer Drug-Eluting Stents. , 2017, JACC. Cardiovascular interventions.

[14]  J. Jeppesen,et al.  10-Year Clinical Outcome After Randomization to Treatment by Sirolimus- or Paclitaxel-Eluting Coronary Stents. , 2017, Journal of the American College of Cardiology.

[15]  F. Eberli,et al.  Ten-year clinical outcomes of first-generation drug-eluting stents: the Sirolimus-Eluting vs. Paclitaxel-Eluting Stents for Coronary Revascularization (SIRTAX) VERY LATE trial. , 2016, European heart journal.

[16]  J. Southard,et al.  Very late stent thrombosis with second generation drug eluting stents compared to bare metal stents: Network meta‐analysis of randomized primary percutaneous coronary intervention trials , 2016, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[17]  A. Kaltoft,et al.  Safety and Efficacy of Everolimus- Versus Sirolimus-Eluting Stents: 5-Year Results From SORT OUT IV. , 2016, Journal of the American College of Cardiology.

[18]  M. Savage,et al.  "Very" very late stent thrombosis: acute myocardial infarction from drug-eluting stent thrombosis more than 5 years after implantation. , 2014, The Journal of invasive cardiology.

[19]  H. Suryapranata,et al.  First-generation versus second-generation drug-eluting stents in current clinical practice: updated evidence from a comprehensive meta-analysis of randomised clinical trials comprising 31 379 patients , 2014, Open Heart.

[20]  Michael Joner,et al.  Risk of stent thrombosis among bare-metal stents, first-generation drug-eluting stents, and second-generation drug-eluting stents: results from a registry of 18,334 patients. , 2013, JACC. Cardiovascular interventions.

[21]  H. Suryapranata,et al.  Safety and efficacy outcomes of first and second generation durable polymer drug eluting stents and biodegradable polymer biolimus eluting stents in clinical practice: comprehensive network meta-analysis , 2013, BMJ.

[22]  G. Stone,et al.  Incidence and predictors of coronary stent thrombosis: evidence from an international collaborative meta-analysis including 30 studies, 221,066 patients, and 4276 thromboses. , 2013, International journal of cardiology.

[23]  P. Serruys,et al.  Everolimus-eluting stent versus bare-metal stent in ST-segment elevation myocardial infarction (EXAMINATION): 1 year results of a randomised controlled trial , 2012, The Lancet.

[24]  G. Stone,et al.  Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis , 2012, The Lancet.

[25]  J. Spertus,et al.  Clinical presentation, management, and outcomes of angiographically documented early, late, and very late stent thrombosis. , 2012, JACC. Cardiovascular interventions.

[26]  H. Bøtker,et al.  Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT OUT III): a randomised controlled superiority trial , 2010, The Lancet.

[27]  A. Kastrati,et al.  Randomized, non-inferiority trial of three limus agent-eluting stents with different polymer coatings: the Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents (ISAR-TEST-4) Trial. , 2009, European heart journal.

[28]  E. Hannan,et al.  Safety and Efficacy of Drug-Eluting and Bare Metal Stents: Comprehensive Meta-Analysis of Randomized Trials and Observational Studies , 2009, Circulation.

[29]  F. Verheugt,et al.  Predictors of coronary stent thrombosis: the Dutch Stent Thrombosis Registry. , 2009, Journal of the American College of Cardiology.

[30]  Simon Wandel,et al.  Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis , 2007, The Lancet.

[31]  William Wijns,et al.  A Cause for Concern , 2007 .

[32]  Marco Valgimigli,et al.  Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. , 2007, The New England journal of medicine.

[33]  Neville Kukreja,et al.  Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study , 2007, The Lancet.

[34]  Seung‐Jung Park,et al.  Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up. , 2006, The American journal of cardiology.

[35]  F. Eberli,et al.  Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. , 2005, The New England journal of medicine.

[36]  P. Grambsch,et al.  Proportional hazards tests and diagnostics based on weighted residuals , 1994 .

[37]  P. Serruys,et al.  Stent thrombosis. , 2010, Journal of the American College of Cardiology.